GlassScriptPhysician profile
Walter Plummer Griffey
NPI 1295708469
$3,089.06
in general payments reported to CMS, 2019-2025
23 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $199 · 2021: $321 · 2022: $366 · 2023: $506 · 2024: $718 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,054.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $297.58 | 2019-2025 | |
| Lilly USA, LLC | $220.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.07 | 2021-2025 | Jardiance |
| Abbvie INC. | $195.49 | 2021-2025 | |
| Mylan Specialty L.P. | $172.56 | 2019-2024 | Yupelri |
| Pfizer INC. | $171.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $130.64 | 2022-2025 | Farxiga |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $81.85 | 2019-2020 | |
| Amarin Pharma, INC. | $60.16 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.95 | 2020-2025 | Xifaxan |
| Eisai INC. | $45.16 | 2020 | |
| Amgen INC. | $43.30 | 2021-2025 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $37.13 | 2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.59 | 2019-2024 | Veozah |
| Dexcom, INC. | $31.82 | 2021-2022 | |
| Viatris Specialty LLC | $31.43 | 2025 | Yupelri |
| Allergan, INC. | $27.97 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $23.18 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $21.48 | 2024 | Keveyis |
| Esperion Therapeutics, INC. | $18.17 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Griffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.